What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds? Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams.In this episode you’ll learn:- Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators. - The three traits VCs demand in first-time biotech CEOs during a funding slump. - How AI-driven platforms like Isomorphic Labs raised mega-rounds in a down market. - Immunology’s surge and why oncology startups are pivoting. - Board-level recruiting tactics that de-risk your Series B.🎙️ Guest: William Holodnak | Founder and President of Occam Global🔗 Connect with Bill: LinkedIn📌 Chapters:00:00 Intro05:45 Cambridge—“the Florence of Biotech” origin story08:20 FDA layoffs: threat or opportunity?13:30 Biotech venture capital mood swings & funding checkpoints18:00 What VCs really screen for in scientific founders25:05 The “horses for courses” CEO model explained33:00 Hot therapeutic areas: AI drug discovery, immunology, repurposing38:30 Why boards need operators, not just investors47:00 Career improvisation: William’s closing adviceFor transcripts, check out the podcast website - www.lifesciencespod.com

Ver todos los episodios